Simulations Plus Releases ADMET Predictor® (X.2)
April 27 2021 - 8:30AM
Business Wire
Industry-driven enhancements further
establish ADMET Predictor® as the preferred platform for discovery
PBPK simulations
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemical, and consumer goods industries, today
announced that it has released version 10.2 of its flagship machine
learning modeling platform, ADMET Predictor®. The new release will
be marketed as APX.2.
Key enhancements in APX.2 include:
- New capabilities in the High Throughput Pharmacokinetic (HTPK)
Simulation Module which integrates machine learning and
physiologically based pharmacokinetic (PBPK) technologies to guide
lead selection
- New intravenous (IV) bolus route of administration to
complement oral dosing options
- Multi-dosing for more complex administration regimens
- Plasma concentration versus time curve overlay for easy
comparison across compounds
- Additional options for dose optimization to support universal
safety and efficacy definitions
- Dose optimization available through the MedChem Designer™
interface for real-time evaluation
- Enhanced mutagenic risk rules which improve accuracy for the
standard Ames mutagenicity assay
- Extended software parallelization to significantly improve
performance for cheminformatic tasks
- Upgraded command line options to automate common applications
of the software
- Improved user experience with added options to customize
spreadsheet displays
Dr. David Miller, vice president of ADMET cheminformatics, said:
“APX.2 enhances the industry-leading discovery PBPK modeling
capabilities within ADMET Predictor and cements the program as the
premier environment for ADMET property prediction modeling. The
R&D collaborations with our large pharmaceutical partner
established the functionality requirements in the HTPK Simulation
Module necessary to bridge communication between discovery and
early development, and the new options for implementation provide
the flexibility needed to fit almost any company’s internal
workflow processes.”
“With capabilities to perform time-dependent mechanistic PK
simulations at the rate of over 100 compounds per second, the
exploratory nature of our discovery PBPK platform takes on its full
meaning as it is deployed in pharmaceutical and biotechnology
companies worldwide,” added Dr. Eric Jamois, director for key
accounts and strategic alliances. “The accelerated growth in the
ADMET Predictor product line revenue in 2QFY21 reflects this
increased adoption, and we look forward to the positive momentum
continuing as APX.2 is rolled out to the global user
community.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a leading provider of modeling and
simulation software and consulting services supporting drug
discovery, development research, and regulatory submissions. With
our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer
solutions which bridge machine learning, physiologically based
pharmacokinetics, quantitative systems pharmacology/toxicology, and
population PK/PD modeling approaches. Our technology is licensed
and applied by major pharmaceutical, biotechnology, chemical,
consumer goods companies and regulatory agencies worldwide. For
more information, visit our website at www.simulations-plus.com.
Follow us on Twitter | Read our Environmental, Social, and
Governance (ESG) Report.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210427005396/en/
Simulations Plus Investor Relations
Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com
Hayden IR Mr. Cameron Donahue
651-653-1854 slp@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024